• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

长效卡博特韦是否是有生育潜力女性的暴露前预防选择？

Is Long-acting Cabotegravir a Pre-exposure Prophylaxis Option for Women of Childbearing Potential?

作者信息

Sahloff Eric G, Hamons Nikki, Baumgartner Kevin, Duggan Joan M

机构信息

University of Toledo College of Pharmacy and Pharmaceutical Sciences, Toledo, Ohio, USA.

Department of Pharmacy, University of Toledo Medical Center, Toledo, Ohio, USA.

出版信息

Open Forum Infect Dis. 2022 May 11;9(7):ofac230. doi: 10.1093/ofid/ofac230. eCollection 2022 Jul.

DOI:10.1093/ofid/ofac230
PMID:35836749
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9274437/
Abstract

Long-acting cabotegravir (CAB-LA) provides an exciting new option for pre-exposure prophylaxis (PrEP) in multiple populations. In this Perspective, we consider the unique pharmacokinetics of CAB-LA and the potential impact on the prescribing of CAB-LA, specifically in cis-women of reproductive potential.

摘要

长效卡博特韦（CAB-LA）为多人群的暴露前预防（PrEP）提供了一个令人兴奋的新选择。在这篇观点文章中，我们探讨了CAB-LA独特的药代动力学以及对CAB-LA处方的潜在影响，特别是对有生殖潜力的顺性别女性的影响。

相似文献

1
Is Long-acting Cabotegravir a Pre-exposure Prophylaxis Option for Women of Childbearing Potential?长效卡博特韦是否是有生育潜力女性的暴露前预防选择？
Open Forum Infect Dis. 2022 May 11;9(7):ofac230. doi: 10.1093/ofid/ofac230. eCollection 2022 Jul.
2
Transgender Women's Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP).跨性别女性在接受长效注射型卡替拉韦（CAB-LA）用于 HIV 暴露前预防（PrEP）时，对定制注射递药策略的障碍、促进因素和偏好。
AIDS Behav. 2021 Dec;25(12):4180-4192. doi: 10.1007/s10461-021-03357-y. Epub 2021 Jul 3.
3
2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis.2-羟丙基-β-环糊精增强纳米流体植入物中卡博特韦的药代动力学用于HIV暴露前预防
J Control Release. 2019 Jul 28;306:89-96. doi: 10.1016/j.jconrel.2019.05.037. Epub 2019 May 25.
4
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).通过评估每 4 或 8 周给药的长效卡替拉韦和利匹韦林的 HIV-1 临床试验，患者报告结果在 1 年内的情况（ATLAS-2M）。
Patient. 2021 Nov;14(6):849-862. doi: 10.1007/s40271-021-00524-0. Epub 2021 May 31.
5
Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials.用于HIV-1暴露前预防的长效注射用抗逆转录病毒药物的安全性和药代动力学特征：随机试验的系统评价和荟萃分析
Front Pharmacol. 2021 Jul 7;12:664875. doi: 10.3389/fphar.2021.664875. eCollection 2021.
6
Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States.扩大艾滋病预防选项菜单：在美国 II 期试验背景下使用长效注射用卡替拉韦作为 PrEP 的经验定性研究。
AIDS Behav. 2018 Nov;22(11):3540-3549. doi: 10.1007/s10461-017-2017-x.
7
Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection.在急性 SHIV 感染期间接受 cabotegravir 长效制剂用于暴露前预防的猕猴中出现耐药性。
Nat Commun. 2019 May 1;10(1):2005. doi: 10.1038/s41467-019-10047-w.
8
9
Preferential Initiation of Long-Acting Injectable Versus Oral HIV Pre-Exposure Prophylaxis Among Women Who Inject Drugs.注射毒品女性中长效注射剂与口服艾滋病病毒暴露前预防的优先启动情况
Clin Infect Dis. 2025 Mar 17;80(3):621-625. doi: 10.1093/cid/ciae450.
10
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.用于预防HIV的卡博特韦长效注射用混悬液的满意度和可接受性：来自ECLAIR试验的患者观点
HIV Clin Trials. 2018 Aug;19(4):129-138. doi: 10.1080/15284336.2018.1511346. Epub 2018 Nov 16.

引用本文的文献

1
From pregnancy to beyond: renewed emphasis on comprehensive HIV prevention in South Africa.从孕期到产后：南非重新强调全面预防艾滋病毒
AIDS. 2025 Mar 15;39(4):470-474. doi: 10.1097/QAD.0000000000004100. Epub 2025 Feb 27.
2
The experience of healthcare workers to HIV pre-exposure prophylaxis (PrEP) implementation in low- and middle-income countries: a systematic review and qualitative meta-synthesis.医护人员在中低收入国家实施艾滋病毒暴露前预防（PrEP）的经验：系统评价和定性荟萃分析。
Front Public Health. 2023 Aug 24;11:1224461. doi: 10.3389/fpubh.2023.1224461. eCollection 2023.
3
Knowledge domain and emerging trends in HIV pre-exposure prophylaxis: A visualization analysis CiteSpace.HIV暴露前预防的知识领域与新兴趋势：一种基于CiteSpace的可视化分析
Front Microbiol. 2023 Mar 16;14:1099132. doi: 10.3389/fmicb.2023.1099132. eCollection 2023.

本文引用的文献

1
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.卡博特韦用于女性艾滋病毒 1 型的预防：来自 HPTN 084 的结果，一项 3 期、随机临床试验。
Lancet. 2022 May 7;399(10337):1779-1789. doi: 10.1016/S0140-6736(22)00538-4. Epub 2022 Apr 1.
2
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.多替拉韦与恩曲他滨和富马酸替诺福韦艾拉酚胺或富马酸替诺福韦二吡呋酯，以及依非韦伦、恩曲他滨和富马酸替诺福韦二吡呋酯用于孕期启动的HIV抗逆转录病毒治疗方案的疗效和安全性（IMPAACT 2010/VESTED）：一项多中心、开放标签、随机、对照、3期试验。
Lancet. 2021 Apr 3;397(10281):1276-1292. doi: 10.1016/S0140-6736(21)00314-7.
3
Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy.HIV 感染孕妇使用整合酶抑制剂与出生缺陷和围生期结局的风险。
AIDS. 2021 Feb 2;35(2):219-226. doi: 10.1097/QAD.0000000000002719.
4
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.长效注射用卡替拉韦在未感染 HIV 的成年人中的尾部阶段安全性、耐受性和药代动力学：HPTN 077 试验的二次分析。
Lancet HIV. 2020 Jul;7(7):e472-e481. doi: 10.1016/S2352-3018(20)30106-5. Epub 2020 Jun 1.
5
Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.简要报告：在参加 HPTN 077 的未感染 HIV 的女性中，激素避孕的使用与卡替拉韦的药代动力学。
J Acquir Immune Defic Syndr. 2020 Sep 1;85(1):93-97. doi: 10.1097/QAI.0000000000002409.
6
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.多替拉韦与依非韦伦在晚期妊娠开始抗 HIV 治疗的女性中的应用（DolPHIN-2）：一项开放标签、随机对照试验。
Lancet HIV. 2020 May;7(5):e332-e339. doi: 10.1016/S2352-3018(20)30050-3.
7
Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.博茨瓦纳开展的一项观察性研究：在孕期开始使用多替拉韦或依非韦伦为基础的抗逆转录病毒治疗的安全性比较。
Lancet Glob Health. 2018 Jul;6(7):e804-e810. doi: 10.1016/S2214-109X(18)30218-3. Epub 2018 Jun 4.
8
Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women.口服卡博特韦对健康成年女性含左炔诺孕酮/炔雌醇口服避孕药药代动力学无影响。
Br J Clin Pharmacol. 2017 Jul;83(7):1499-1505. doi: 10.1111/bcp.13236. Epub 2017 Feb 14.
9
Formulation and pharmacology of long-acting cabotegravir.长效卡博特韦的制剂与药理学
Curr Opin HIV AIDS. 2015 Jul;10(4):239-45. doi: 10.1097/COH.0000000000000168.
10
GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects.在健康受试者中单次长效注射给药后，GSK1265744 在血浆和组织中的药代动力学。
J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):481-6. doi: 10.1097/QAI.0000000000000301.